Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glucosidase, alpha | Starlite/ChEMBL | No references |
Homo sapiens | geminin, DNA replication inhibitor | Starlite/ChEMBL | No references |
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Homo sapiens | _UBC13, UbcH-ben, UbcH13 | Starlite/ChEMBL | No references |
Mus musculus | RAR-related orphan receptor gamma | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | Hypothetical 65.5 kDa Trp-Asp repeats containing protein F02E8.5 inchromosome X | geminin, DNA replication inhibitor | 209 aa | 176 aa | 27.8 % |
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Plasmodium falciparum | ubiquitin-conjugating enzyme E2, putative | _UBC13, UbcH-ben, UbcH13 | 152 aa | 153 aa | 32.0 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | ubiquitin-conjugating enzyme E2, putative | 0.0046 | 0.0085 | 1 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.006 | 0.0329 | 0.0329 |
Echinococcus multilocularis | PAK box P21 Rho binding | 0.0054 | 0.0222 | 0.0198 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0053 | 0.0204 | 0.8995 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.0329 | 0.0329 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0053 | 0.0204 | 0.0725 |
Loa Loa (eye worm) | hypothetical protein | 0.0053 | 0.0204 | 0.0204 |
Echinococcus multilocularis | serine:threonine protein kinase PAK 3 | 0.0054 | 0.0222 | 0.0198 |
Echinococcus granulosus | lysosomal alpha glucosidase | 0.0197 | 0.2683 | 0.292 |
Echinococcus multilocularis | ubiquitin conjugating enzyme E2 N | 0.0046 | 0.0085 | 0.0046 |
Echinococcus granulosus | PAK box P21 Rho binding | 0.0053 | 0.0204 | 0.0178 |
Brugia malayi | Protein kinase domain | 0.0054 | 0.0222 | 0.0222 |
Schistosoma mansoni | wiskott-aldrich syndrome protein | 0.0053 | 0.0204 | 0.0725 |
Brugia malayi | P21-Rho-binding domain containing protein | 0.0053 | 0.0204 | 0.0204 |
Schistosoma mansoni | ubiquitin conjugating enzyme 13 | 0.0046 | 0.0085 | 0.0301 |
Brugia malayi | Glycosyl hydrolases family 31 protein | 0.0197 | 0.2683 | 0.2683 |
Trypanosoma cruzi | ubiquitin-conjugating enzyme E2, putative | 0.0046 | 0.0085 | 1 |
Entamoeba histolytica | protein kinase, putative | 0.0054 | 0.0222 | 1 |
Schistosoma mansoni | alpha-glucosidase | 0.0169 | 0.2211 | 0.7842 |
Trichomonas vaginalis | STE family protein kinase | 0.0054 | 0.0222 | 1 |
Trichomonas vaginalis | STE family protein kinase | 0.0054 | 0.0222 | 1 |
Trichomonas vaginalis | STE family protein kinase | 0.0054 | 0.0222 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0053 | 0.0204 | 0.8995 |
Echinococcus granulosus | serine:threonine protein kinase PAK 3 | 0.0054 | 0.0222 | 0.0198 |
Echinococcus multilocularis | lysosomal alpha glucosidase | 0.0197 | 0.2683 | 0.292 |
Trichomonas vaginalis | ubiquitin-conjugating enzyme E2, putative | 0.0046 | 0.0085 | 0.2319 |
Giardia lamblia | Kinase, STE STE20 | 0.0054 | 0.0222 | 0.5 |
Entamoeba histolytica | protein kinase, putative | 0.0054 | 0.0222 | 1 |
Loa Loa (eye worm) | ubiquitin conjugating enzyme protein 13 | 0.0046 | 0.0085 | 0.0085 |
Brugia malayi | P21-Rho-binding domain containing protein | 0.0053 | 0.0204 | 0.0204 |
Entamoeba histolytica | protein kinase, putative | 0.0054 | 0.0222 | 1 |
Trypanosoma brucei | ubiquitin-protein ligase, putative | 0.0046 | 0.0085 | 1 |
Loa Loa (eye worm) | glycosyl hydrolase family 31 protein | 0.0044 | 0.0043 | 0.0043 |
Schistosoma mansoni | alpha-glucosidase | 0.0169 | 0.2211 | 0.7842 |
Schistosoma mansoni | protein kinase | 0.0054 | 0.0222 | 0.0789 |
Schistosoma mansoni | tyrosine kinase | 0.0053 | 0.0204 | 0.0725 |
Schistosoma mansoni | protein kinase | 0.0054 | 0.0222 | 0.0789 |
Trichomonas vaginalis | ubiquitin-conjugating enzyme E2, putative | 0.0046 | 0.0085 | 0.2319 |
Schistosoma mansoni | protein kinase | 0.0053 | 0.0204 | 0.0725 |
Toxoplasma gondii | ubiquitin-conjugating enzyme subfamily protein | 0.0046 | 0.0085 | 1 |
Brugia malayi | Ubiquitin conjugating enzyme protein 13 | 0.0046 | 0.0085 | 0.0085 |
Leishmania major | ubiquitin-conjugating enzyme e2, putative | 0.0046 | 0.0085 | 1 |
Echinococcus multilocularis | neural Wiskott Aldrich syndrome protein | 0.0053 | 0.0204 | 0.0178 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 0.0329 | 0.0329 |
Echinococcus multilocularis | PAK box P21 Rho binding | 0.0053 | 0.0204 | 0.0178 |
Plasmodium vivax | ubiquitin-conjugating enzyme E2 N, putative | 0.0046 | 0.0085 | 0.5 |
Schistosoma mansoni | alpha glucosidase | 0.0044 | 0.0043 | 0.0153 |
Schistosoma mansoni | hypothetical protein | 0.0053 | 0.0204 | 0.0725 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 0.0329 | 0.0329 |
Schistosoma mansoni | hypothetical protein | 0.0053 | 0.0204 | 0.0725 |
Plasmodium falciparum | ubiquitin-conjugating enzyme E2 N, putative | 0.0046 | 0.0085 | 0.5 |
Brugia malayi | WH1 domain containing protein | 0.0053 | 0.0204 | 0.0204 |
Entamoeba histolytica | ubiquitin-conjugating enzyme family protein | 0.0046 | 0.0085 | 0.2319 |
Loa Loa (eye worm) | ubiquitin conjugating enzyme protein 13 | 0.0046 | 0.0085 | 0.0085 |
Echinococcus granulosus | geminin | 0.0205 | 0.2819 | 0.307 |
Schistosoma mansoni | protein kinase | 0.0054 | 0.0222 | 0.0789 |
Echinococcus multilocularis | p21 activated protein kinase 1 Dpak1 | 0.0054 | 0.0222 | 0.0198 |
Entamoeba histolytica | hypothetical protein | 0.0053 | 0.0204 | 0.8995 |
Echinococcus granulosus | 3'partial|serine:threonine protein kinase PAK 2 | 0.0053 | 0.0204 | 0.0178 |
Brugia malayi | Glycosyl hydrolases family 31 protein | 0.0044 | 0.0043 | 0.0043 |
Entamoeba histolytica | p21-activated kinase | 0.0054 | 0.0222 | 1 |
Echinococcus granulosus | serine:threonine protein kinase PAK 4 | 0.0568 | 0.9086 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 0.2819 | 1 |
Echinococcus multilocularis | serine:threonine protein kinase PAK 3 | 0.0054 | 0.0222 | 0.0198 |
Loa Loa (eye worm) | STE/STE20/PAKB protein kinase | 0.0621 | 1 | 1 |
Brugia malayi | ubiquitin conjugating enzyme protein 13 | 0.0046 | 0.0085 | 0.0085 |
Echinococcus granulosus | neural Wiskott Aldrich syndrome protein | 0.0053 | 0.0204 | 0.0178 |
Trichomonas vaginalis | STE family protein kinase | 0.0054 | 0.0222 | 1 |
Entamoeba histolytica | protein kinase, putative | 0.0054 | 0.0222 | 1 |
Echinococcus granulosus | ubiquitin conjugating enzyme E2 N | 0.0046 | 0.0085 | 0.0046 |
Onchocerca volvulus | 0.0114 | 0.1253 | 0.5 | |
Echinococcus multilocularis | lysosomal alpha glucosidase | 0.0197 | 0.2683 | 0.292 |
Trichomonas vaginalis | STE family protein kinase | 0.0054 | 0.0222 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0053 | 0.0204 | 0.0725 |
Echinococcus granulosus | p21 activated protein kinase 1 Dpak1 | 0.0054 | 0.0222 | 0.0198 |
Echinococcus granulosus | serine:threonine protein kinase PAK 3 | 0.0054 | 0.0222 | 0.0198 |
Loa Loa (eye worm) | P21-Rho-binding domain-containing protein | 0.0053 | 0.0204 | 0.0204 |
Echinococcus multilocularis | geminin | 0.0205 | 0.2819 | 0.307 |
Loa Loa (eye worm) | glycosyl hydrolase family 31 protein | 0.0197 | 0.2683 | 0.2683 |
Echinococcus multilocularis | serine:threonine protein kinase PAK 4 | 0.0568 | 0.9086 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 0.2819 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 1.524 uM | PUBCHEM_BIOASSAY: Dose Response confirmation of uHTS for the identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay reconfirm. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485273, AID485343, AID493155] | ChEMBL. | No reference |
IC50 (functional) | = 6.146 uM | PUBCHEM_BIOASSAY: Dose Response confirmation of uHTS for the identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485273, AID485343, AID493182] | ChEMBL. | No reference |
IC50 (functional) | > 20 uM | PUBCHEM_BIOASSAY: Dose Response confirmation of UBC13 Polyubiquitin Inhibitors using a Bfl-1 counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485273, AID485343] | ChEMBL. | No reference |
IC50 (functional) | 26.839 uM | PubChem BioAssay. Fluorescence polarization-based biochemical high throughput dose response assay for inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 0.4467 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 0.5623 um | PUBCHEM_BIOASSAY: qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 0.8913 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease. (Class of assay: confirmatory) [Related pubchem assays: 997 ] | ChEMBL. | No reference |
Potency (functional) | = 0.8913 um | PUBCHEM_BIOASSAY: qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease. (Class of assay: confirmatory) [Related pubchem assays: 1467, 2100, 2112, 1473, 1466 ] | ChEMBL. | No reference |
Potency (functional) | 1.4716 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 1.4716 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 3.5481 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | 16.3601 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 22.3872 um | PUBCHEM_BIOASSAY: Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization. This assay monitors tau fibrillation by fluorescence polarization (FP) of Alexa 594-labeled K18 P301L, which does not fibrillize readily but incorporates into growing filaments of unlabeled tau. (Class of assay: confirmatory) [Related pubchem assays: 596 ] | ChEMBL. | No reference |
Potency (functional) | = 25.1189 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
Potency (functional) | 25.1189 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of JMJD2A-Tudor Domain. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504402] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 | ||
Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.